Latina patients with breast cancer given more information more likely to enter clinical trials
the ONA take:
According to new findings presented at the American Association of Cancer Research conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, Latina patients with breast cancer given information about clinical trials in various way had much more awareness of clinical trials versus women who received the typical information.
One particular method was culturally sensitive, computer-based videos that provided information on breast cancer clinical trials.
For the study, investigators enrolled 71 Latina patients with breast cancer who were eligible to take part in clinical trial at the Cancer Therapy and Research Center in San Antonio. Researchers are still recruiting women for the study. Participants randomly assigned to receive additional information watched culturally-sensitive, computer-based videos, read a booklet, and had assistance from a patient navigator.
Women with additional information were more of aware of how to participate in a clinical trial and the risks and benefits. Women in the process of participating in a breast cancer clinical trial rose from 38 to 75% after being provided the additional information about clinical trials. The researchers hope to expand the study to include patients with all types of cancer.
Latina patients with breast cancer had much more awareness of clinical trials.
Latina breast cancer patients provided with information about clinical trials in multiple ways, including a culturally sensitive, computer-based video on breast cancer clinical trials, had much greater awareness of clinical trials compared with patients who received usual-care information, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
After receiving the additional information, the proportion of Latina breast cancer patients taking steps toward participating in a clinical trial increased from 38 percent to 75 percent.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|